SEC Form 4 · accession 0001562180-18-003802
BIO-TECHNE Corp · TECH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles R. Kummeth
Officer — Chief Executive Officer · Director
Period of report
Aug 18, 2018
Accepted (ET)
Aug 31, 2018 · 4:39 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000842023
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 18, 2018 | F | 1,338 | $180.50 | D | 92,176 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | holding | — | — | — | — | — | Common Stock | 24,979 | 24,979 | D |
| Restricted Stock UnitsF2,F4 | — | holding | — | — | — | — | — | Common Stock | 21,291 | 21,291 | D |
| Restricted Stock UnitsF2,F5 | — | holding | — | — | — | — | — | Common Stock | 16,918 | 16,918 | D |
| Stock Option (Right to Buy)F6 | $108.49 | holding | — | — | — | — | Aug 7, 2022 | Common Stock | 79,517 | 79,517 | D |
| Stock Option (Right to Buy)F7 | $106.59 | holding | — | — | — | — | Aug 18, 2023 | Common Stock | 102,779 | 102,779 | D |
| Stock Option (Right to Buy)F3 | $106.59 | holding | — | — | — | — | Aug 18, 2023 | Common Stock | 154,169 | 154,169 | D |
| Stock Option (Right to Buy)F8 | $86.25 | holding | — | — | — | — | Apr 1, 2021 | Common Stock | 46,316 | 46,316 | D |
| Stock Option (Right to Buy)F8 | $67.46 | holding | — | — | — | — | Apr 1, 2020 | Common Stock | 65,000 | 65,000 | D |
| Stock Option (Right to Buy)F8 | $67.46 | holding | — | — | — | — | Apr 1, 2020 | Common Stock | 50,000 | 50,000 | D |
| Stock Options (Right to buy)F9 | $177.32 | holding | — | — | — | — | Aug 8, 2025 | Common Stock | 60,222 | 60,222 | D |
| Stock Options (Right to buy)F5 | $177.32 | holding | — | — | — | — | Aug 8, 2025 | Common Stock | 90,334 | 90,334 | D |
| Stock Options (Right to buy)F4 | $125.05 | holding | — | — | — | — | Aug 9, 2024 | Common Stock | 117,342 | 117,342 | D |
| Stock Options (Right to buy)F10 | $125.05 | holding | — | — | — | — | Aug 9, 2024 | Common Stock | 78,228 | 78,228 | D |
| Stock Options (Right to buy)F8 | $94.35 | holding | — | — | — | — | Aug 12, 2021 | Common Stock | 66,849 | 66,849 | D |
Explanation of responses
- F1Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021.
- F10Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021
- F2Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- F3Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F4Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F5Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- F6Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19.
- F7Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.
- F8Fully exercisable
- F9Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022